Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer
PeerJ · 2025
DOI: 10.7717/peerj.20251 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Xueqin Duan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Transcription Factors, DNA Methylation, DNA-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation, Qilu Health Leading Talents Training Project.
Abstract (Originalsprache)
Objective
AT-rich interaction domain 1A (ARID1A), is frequently mutated in cancer, leading to loss-of-function and posing challenges to therapeutic targeting. This study aimed to systematically explore epigenetic regulation of ARID1A, specifically promoter hypermethylation, in gastric cancer (GC) and its functional/immunological consequences.
Methods
We employed multi-omics bioinformatics analyses (UALCAN, cBioPortal, MEXPRESS and UCSC Xena) combined with in vitro functional validation in GC cell lines, including pharmacological demethylation using 5-Aza-2’-deoxycytidine (5-aza-CdR) and mechanistic interrogation via AKT agonism (SC79).
Results
Promoter hypermethylation was identified as a key mechanism silencing ARID1A transcriptional, showing a significant negative correlation between methylation β -values and mRNA expression (Spearman’s ρ = − 0.29, p = 2.06 × 10 −8 ). 5-aza-CdR treatment restored ARID1A expression ( p < 0.001), suppressed malignant phenotypes (proliferation, invasion, and apoptosis resistance), and revealed that ARID1A lose activates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway (elevated p-AKT, p-mTOR) and upregulates PD-L1. Rescue experiments with SC79 reversed 5-aza-CdR’s effects, confirming the ARID1A-PI3K/AKT/mTOR-PD-L1 axis. Integrative analysis linked ARID1A hypermethylation to elevated immune/ESTIMATE scores ( p < 0.05).
Conclusion
ARID1A promoter hypermethylation drives an epigenetic-immune checkpoint cascade in GC. Combined with its association with immune signatures and PD-L1 upregulation, ARID1A hypermethylation emerges as a candidate biomarker for predicting immune checkpoint blockade (ICB) responsiveness and patient stratification in GC. Future studies should evaluate 5-aza-CdR-ICB-AKT inhibitor regimens in advanced models to guide clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Medicine, Qingdao University, Qingdao, Shandong, China.
- Department of Oncology, Qingdao Central Hospital of Health and Rehabilitation University, Qingdao, Shandong, China.
Förderung
- Shandong Provincial Natural Science Foundation
- Qilu Health Leading Talents Training Project
Zitieren
APA
Duan, X., Huo, X., Zhang, Y., Lan, H., Yang, F., Zhang, X., & Zhou, N. (2025). Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer. PeerJ. https://doi.org/10.7717/peerj.20251
Vancouver
Duan X, Huo X, Zhang Y, Lan H, Yang F, Zhang X, et al. Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer. PeerJ. 2025. doi:10.7717/peerj.20251
BibTeX
@article{Duan2025,
author = {Duan, Xueqin and Huo, Xingfa and Zhang, Yuming and Lan, Hongwei and Yang, Fangfang and Zhang, Xiaochun and Zhou, Na},
title = {Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.20251}
}
EUVIMED